New way to safer CAR-T cell therapies – European Biotechnology
European Biotechnology |
New way to safer CAR–T cell therapies
European Biotechnology These adverse effects (AEs), which could be life-threatening, are associated with administration of CAR–T cell therapies and have been managed so far by co-administration of IL6-receptor blockers such as Roche's tocilizumab, which can prevent CRS but … |
